Matt Lawler is an Entrepreneur-in-Residence at Blackbird Laboratories, where his mission is to create new ventures that turn exciting science into successful therapies.

Prior to joining Blackbird, Matt co-founded TriBiotica LLC, a company developing oncology therapies utilizing in situ activatable chemistry to target previously un-druggable tumor markers. Matt co-invented TriBiotica’s core technology and designed discovery and preclinical stage experimental programs. As President, he led the company’s financing strategy, developed business operations, and structured the regulatory development path of lead assets. Previously, Matt was a preclinical development manager at CytoCure and Director of Molecular Biology Projects at ACGT, Inc. Matt earned his Bachelor’s Degree in Biology from the University of Wisconsin-Madison.